In Vitro Antibacterial Activity of Imipenem/Relebactam against Clinical Isolates in Japan

ABSTRACT Relebactam is a novel β-lactamase inhibitor of Ambler class A and C β-lactamases that has been developed in combination with imipenem/cilastatin for the treatment of carbapenem-resistant bacterial infections. In this study, we evaluated the in vitro antibacterial activity of imipenem/releba...

Full description

Bibliographic Details
Published in:Microbiology Spectrum
Main Authors: Dai Kurihara, Satoru Matsumoto, Naoko Kishi, Yoshikazu Ishii, Masahiko Mori
Format: Article
Language:English
Published: American Society for Microbiology 2022-04-01
Subjects:
carbapenem-resistant
imipenem
relebactam
susceptibility
Online Access:https://journals.asm.org/doi/10.1128/spectrum.02235-21

Internet

https://journals.asm.org/doi/10.1128/spectrum.02235-21

Similar Items